Search This Blog

Tuesday, March 22, 2016

Amgen And UCB Announce Positive Top-Line Results From Phase 3 Study Evaluating Romosozumab In Men With Osteoporosis

BRIDGE Study Met Primary and All Secondary Endpoints
Results Add to Growing Body of Positive Late-Stage Data Evaluating Efficacy and Safety of Romosozumab in Patients With Osteoporosis


Amgen - Investors - RSS Content
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)